Changes and safety analysis of blood pressure and heart failure indexes in HFrEF patients with hyperten-sion after treatment with sarcubatrix valsartan sodium and dagelin

Shao Bolin; Wang Shaoxin

doi:10.3969/j.issn.1674-4055.2024.07.22

Abstract：Objective To analyze the changes and safety of blood pressure and heart failure indicators in patients with heart failure with reduced ejection fraction(HFrEF)and hypertension after treatment with Sacubatrovsartan sodium and Daggligin.Methods 168 patients with HFrEF combined with hypertension admitted to the Department of Cardiovascular Medicine,School of Clinical Medicine,Henan University of Science and Technology,from January 2021 to June 2022 were selected and divided into two groups,the nosyntropic group(n=82)and the combined group(n=86),using the envelope randomization method.Patients in the Noxintol group were treated with sacubitril valsartan sodium 100 mg twice daily,and in the combined group,oral dagliflozin 5 mg was administered once daily in the morning on the basis of the Noxintol group,and patients in both groups were treated continuously for 3 months.Compare the level of blood pressure,cardiac function and exercise endurance before and after treatment,detect the difference of serum amino-terminal brain natriuretic peplide precursor(NT-proBNP),interleukin-33(IL-33)and other factors before and after treatment in the two groups and count the safety of medication in the two groups.Results Comparison of blood pressure,cardiac function and 6-minute walking distance(6MWD)between the two groups before treatment did not show statistical differences(P＞0.05).Compared with the pre-treatment,left ventricular ejection fraction(LVEF)and 6MWD of the two groups increased significantly after treatment,and the combined group was higher than that of the Nosinostat group,and the differences were statistically significant(P＜0.05),while blood pressure,left ventricular end-diastolic internal diameter(LVEDD)and left ventricular end-systolic internal diameter(LVESD)of the two groups decreased significantly after treatment,and the combined group was lower than that of the Nosinostat group,and the differences were statistically significant(P＜0.05).Comparison of serum NT-proBNP,high-sensitivity-C-reactive protein(hs-CRP),IL-33,galactose lectin-3(Gal-3),and soluble tumor factor 2 inhibitor(sST2)between the two groups before treatment did not show any statistically significant difference(P＞0.05).Compared with pre-treatment,NT-proBNP,hs-CRP,IL-33,Gal-3,and sST2 decreased significantly after treatment in both groups,and the combined group was lower than that of the nociceptor group,and the differences were statistically significant(P＜0.05).The cumulative adverse reaction rate of hypotension,hyperkalemia,urinary tract infection and gastric upset in the combined group was 12.79％,which was not statistically different from 9.76％in the nosinostat group(P＞0.05).Conclusion In HFrEF patients with hypertension,the treatment of Sakubatrovsartan sodium combined with Daggligin can improve cardiac function,reduce the expression of Gal-3,sST2 and other factors,improve exercise tolerance,and will not increase adverse reactions.